INVESTORS

2014 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/18/14Enumeral and Merck Form Collaboration for Predicting Clinical Drug Response with Human-driven Immune Profiling Platform
CAMBRIDGE, Mass.--December 18, 2014--Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), today announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being... 
Printer Friendly Version
12/04/14Enumeral Appoints Robert L. Van Nostrand to its Board of Directors
CAMBRIDGE, Mass.--December 4, 2014--Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today it has appointed Robert L. Van Nostrand to its Board of Directors. Mr. Van Nostrand is a seasoned biotechnology executive with an extensive background in finance, operations and accounting in public biotechnology companies in all stages of development. For 21 years, he served in executive leadership positions at OSI Pharmaceuticals, including Chief Compliance Officer, Chief Financial Officer and... 
Printer Friendly Version
11/11/14Enumeral Reports Third Quarter 2014 Financial Results
CAMBRIDGE, Mass.--November 14, 2014--Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), today reported its financial results for the three and nine months ended September 30, 2014. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission.“With a significant financing closed in the third quarter, we are well positioned to advance our antibody programs that target immune checkpoint prote... 
Printer Friendly Version
10/21/14Enumeral Appoints Isabel Chiu, Ph.D., as Vice President of Translational and Clinical Sciences
CAMBRIDGE, Mass.--October 21, 2014--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that M. Isabel Chiu, Ph.D., has been appointed Vice President of Translational and Clinical Sciences. Dr. Chiu brings over 20 years of scientific, academic and industry experience in shaping biotechnology programs from research to late-stage development. She is responsible for developing and implementing Enumeral’s internal and external translational programs using human patient-derived tissue sa... 
Printer Friendly Version
09/17/14Enumeral Awarded Phase II SBIR Contract from the National Cancer Institute to Advance Human Tissue Immuno-Oncology Profiling
CAMBRIDGE, Mass.--September 17, 2014--Enumeral (OTCQB:ENUM) has been awarded a Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI) for $999,967 over two years. The company will be developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which it will deploy at two leading medical institutions over the course of the contract. The NCI will be funding the entirety of the program, which will complement Enumeral’s ... 
Printer Friendly Version
09/15/14Enumeral Appoints Kevin Sarney, CPA, as Vice President of Finance and Chief Accounting Officer
CAMBRIDGE, Mass.--September 15, 2014--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that Kevin Sarney, CPA, has been appointed Vice President of Finance and Chief Accounting Officer. Mr. Sarney brings significant finance, accounting, operations and SEC reporting experience to Enumeral having served over 15 years in the life science industry in both early-stage and publicly traded companies. “Kevin’s experiences working with biotechnology companies developing targeted therapies... 
Printer Friendly Version
08/04/14Enumeral Biomedical Raises $21.5 Million from New and Current Investors, Begins Public Trading
-- Enumeral Biomedical Holdings, Inc. (formerly Cerulean Group, Inc.) (OTCQB:ENUM), completes an alternative public offering; Enumeral Biomedical Corp. becomes a wholly owned subsidiary of the Company. --Cambridge, Mass.--August 4, 2014--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral”) today announced the completion of a merger between Enumeral Biomedical Corp. and a subsidiary of Enumeral Biomedical Holdings, Inc., formerly known as Cerulean Group, Inc. Coinciding with the merger, E... 
Printer Friendly Version